South Korea · Delayed Price · Currency is KRW GemVax&KAEL Statistics
Total Valuation
GemVax&KAEL has a market cap or net worth of KRW 503.28 billion. The enterprise value is 544.43 billion.
| Market Cap | 503.28B |
| Enterprise Value | 544.43B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GemVax&KAEL has 43.95 million shares outstanding. The number of shares has increased by 5.85% in one year.
| Current Share Class | 43.95M |
| Shares Outstanding | 43.95M |
| Shares Change (YoY) | +5.85% |
| Shares Change (QoQ) | +2.17% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 5.29% |
| Float | 32.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.91 |
| PB Ratio | 6.81 |
| P/TBV Ratio | 7.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.40 |
| EV / EBITDA | 69.07 |
| EV / EBIT | 145.81 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 1.03.
| Current Ratio | 1.08 |
| Quick Ratio | 0.76 |
| Debt / Equity | 1.03 |
| Debt / EBITDA | 5.95 |
| Debt / FCF | -28.87 |
| Interest Coverage | 1.35 |
Financial Efficiency
Return on equity (ROE) is -21.30% and return on invested capital (ROIC) is 4.12%.
| Return on Equity (ROE) | -21.30% |
| Return on Assets (ROA) | 3.34% |
| Return on Invested Capital (ROIC) | 4.12% |
| Return on Capital Employed (ROCE) | 8.42% |
| Weighted Average Cost of Capital (WACC) | 8.47% |
| Revenue Per Employee | 467.60M |
| Profits Per Employee | -67.18M |
| Employee Count | 182 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 5.33 |
Taxes
| Income Tax | -168.36M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.59% in the last 52 weeks. The beta is 0.82, so GemVax&KAEL's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -77.59% |
| 50-Day Moving Average | 11,177.40 |
| 200-Day Moving Average | 25,517.90 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 195,297 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemVax&KAEL had revenue of KRW 85.10 billion and -12.23 billion in losses. Loss per share was -285.82.
| Revenue | 85.10B |
| Gross Profit | 36.06B |
| Operating Income | 8.70B |
| Pretax Income | -12.40B |
| Net Income | -12.23B |
| EBITDA | 12.85B |
| EBIT | 8.70B |
| Loss Per Share | -285.82 |
Balance Sheet
The company has 35.34 billion in cash and 76.48 billion in debt, with a net cash position of -41.15 billion or -936.12 per share.
| Cash & Cash Equivalents | 35.34B |
| Total Debt | 76.48B |
| Net Cash | -41.15B |
| Net Cash Per Share | -936.12 |
| Equity (Book Value) | 73.92B |
| Book Value Per Share | 1,678.38 |
| Working Capital | 4.73B |
Cash Flow
In the last 12 months, operating cash flow was -919.41 million and capital expenditures -1.73 billion, giving a free cash flow of -2.65 billion.
| Operating Cash Flow | -919.41M |
| Capital Expenditures | -1.73B |
| Depreciation & Amortization | 4.23B |
| Net Borrowing | 15.12B |
| Free Cash Flow | -2.65B |
| FCF Per Share | -60.26 |
Margins
Gross margin is 42.37%, with operating and profit margins of 10.23% and -14.37%.
| Gross Margin | 42.37% |
| Operating Margin | 10.23% |
| Pretax Margin | -14.56% |
| Profit Margin | -14.37% |
| EBITDA Margin | 15.10% |
| EBIT Margin | 10.23% |
| FCF Margin | n/a |
Dividends & Yields
GemVax&KAEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.85% |
| Shareholder Yield | -5.85% |
| Earnings Yield | -2.43% |
| FCF Yield | -0.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemVax&KAEL has an Altman Z-Score of 10.57 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.57 |
| Piotroski F-Score | 6 |